Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)
Ariadna Colomer‐Carbonell, Juan P. Sanabria‐Mazo, Halbert Hernández-Negrín, Xavier Borrás, Carlos Suso‐Ribera, Azucena García‐Palacios, Jordi Muchart, Josep Munuera, Francesco D’Amico, Michael Maes, Jarred Younger, Albert Feliu‐Soler, Antoni Rozadilla‐Sacanell, Juan V. Luciano (2022). Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). , 12(1), DOI: https://doi.org/10.1136/bmjopen-2021-055351.
